Chad Landmon, JD, chair of Intellectual Property and FDA Practice at Axinn, Veltrop & Harkrider, provides a legal perspective on the implications of President Biden’s effort to improve the competitiveness of drug markets.
On July 9, 2021, President Biden signed a sweeping executive order intended to promote a more vibrant and competitive economy. The mandate contained provisions that affect the biosimilars market.
For insight into the significance of these initiatives, The Center for Biosimilars® spoke with Chad Landmon, JD, chair of the Intellectual Property and FDA Practice groups at Axinn, Veltrop & Harkrider, a law firm specializing in antitrust and intellectual property issues based in New York.
The executive order calls for the importation of drugs from Canada to help improve supply and lower prices in the United States. It also directs HHS to support the use of generic and biosimilar agents, and it increases pressure on the Federal Trade Commission to oppose “pay-for-delay” agreements that pharmaceutical companies sometimes employ to keep rival products off the market.
Among its provisions, the executive order also calls upon HHS to produce a comprehensive plan within 45 days to address high prescription drug prices and “price gouging.”
Landmon put these initiatives into context with background information and insight into the likely pharmaceutical industry impact and response.
He discusses the complications inherent in tackling pay-for-delay settlements as these, while not ideal, do carry the benefit of offering parties to a pharmaceutical dispute a way to set a timeline for bringing products to market, thereby avoiding costly litigation that could prevent lower-cost drugs from entering the market for substantially longer periods of time.
Landmon mentions California’s landmark anti–pay-for-delay legislation, signed into law in 2019, that prevents “anything of value” from being exchanged by pharmaceutical companies in exchange for a settlement. This law survived its first legal challenge last year when a federal judge denied a motion for relief by the Association for Accessible Medicines (AAM), a group representing generics and biosimilars manufacturers.
The AAM in a statement issued July 9, 2021, said it is willing to work with the Biden administration to accelerate adoption of lower-cost generics and biosimilars but wants to avoid extension of restrictions on drug dispute settlements such as California has imposed. “The White House should ensure that any new regulations do not restrict the ability to settle patent litigation with brand companies in a procompetitive manner,” the AAM said.
Drug imports from Canada were authorized during the Trump administration. For a recent Center for Biosimilars® article outlining the pros and cons of this initiative, click here.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.